Loading…
A 37‐year‐old Menkes disease patient—Residual ATP7A activity and early copper administration as key factors in beneficial treatment
Menkes disease (MD) is a lethal disorder characterized by severe neurological symptoms and connective tissue abnormalities; and results from malfunctioning of cuproenzymes, which cannot receive copper due to a defective intracellular copper transporting protein, ATP7A. Early parenteral copper‐histid...
Saved in:
Published in: | Clinical genetics 2017-11, Vol.92 (5), p.548-553 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3343-cac854d8981e5c6f85d75a3d6e7f3a6227535e14ffd111e7dc87e5b99838590a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c3343-cac854d8981e5c6f85d75a3d6e7f3a6227535e14ffd111e7dc87e5b99838590a3 |
container_end_page | 553 |
container_issue | 5 |
container_start_page | 548 |
container_title | Clinical genetics |
container_volume | 92 |
creator | Tümer, Z. Petris, M. Zhu, S. Mercer, J. Bukrinski, J. Bilz, S. Baerlocher, K. Horn, N. Møller, L.B |
description | Menkes disease (MD) is a lethal disorder characterized by severe neurological symptoms and connective tissue abnormalities; and results from malfunctioning of cuproenzymes, which cannot receive copper due to a defective intracellular copper transporting protein, ATP7A. Early parenteral copper‐histidine supplementation may modify disease progression substantially but beneficial effects of long‐term treatment have been recorded in only a few patients. Here we report on the eldest surviving MD patient (37 years) receiving early‐onset and long‐term copper treatment. He has few neurological symptoms without connective tissue disturbances; and a missense ATP7A variant, p.(Pro852Leu), which results in impaired protein trafficking while the copper transport function is spared. These findings suggest that some cuproenzymes maintain their function when sufficient copper is provided to the cells; and underline the importance of early initiated copper treatment, efficiency of which is likely to be dependent on the mutant ATP7A function. |
doi_str_mv | 10.1111/cge.13083 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1914582026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1948347936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3343-cac854d8981e5c6f85d75a3d6e7f3a6227535e14ffd111e7dc87e5b99838590a3</originalsourceid><addsrcrecordid>eNp1kTFP3TAUhS1UVF5pB_5AZalLGQJxbhzb49MThUogEKJz5GffVIbECXZClY21G0N_Ib8E00c7IOHlyNJ3zr26h5A9lh-w9A7NTzxgkEvYIgsGSmV5npfvyCKJyhSrYId8iPE6fUFw9Z7sFLLiggFbkN9LCuLx_mFGHZL0raVn6G8wUusi6oh00KNDPz7e_7nE6OykW7q8uhBLqs3o7tw4U-0tTfZ2pqYfBgxU2855F8eQrL2nOtIbnGmTDH2I1Hm6Ro-NMy5ljQH12KUBH8l2o9uIn150l_z4dnS1OslOz4-_r5anmQEoITPaSF5aqSRDbqpGciu4BluhaEBXRSE4cGRl09h0GhTWSIF8rZQEyVWuYZd83eQOob-dMI5156LBttUe-ynWTLGSyyIvqoR-eYVe91PwabtElRJKoeCZ2t9QJvQxBmzqIbhOh7lmef3cT536qf_2k9jPL4nTukP7n_xXSAION8Av1-L8dlK9Oj7aRD4BiTicng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1948347936</pqid></control><display><type>article</type><title>A 37‐year‐old Menkes disease patient—Residual ATP7A activity and early copper administration as key factors in beneficial treatment</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Tümer, Z. ; Petris, M. ; Zhu, S. ; Mercer, J. ; Bukrinski, J. ; Bilz, S. ; Baerlocher, K. ; Horn, N. ; Møller, L.B</creator><creatorcontrib>Tümer, Z. ; Petris, M. ; Zhu, S. ; Mercer, J. ; Bukrinski, J. ; Bilz, S. ; Baerlocher, K. ; Horn, N. ; Møller, L.B</creatorcontrib><description>Menkes disease (MD) is a lethal disorder characterized by severe neurological symptoms and connective tissue abnormalities; and results from malfunctioning of cuproenzymes, which cannot receive copper due to a defective intracellular copper transporting protein, ATP7A. Early parenteral copper‐histidine supplementation may modify disease progression substantially but beneficial effects of long‐term treatment have been recorded in only a few patients. Here we report on the eldest surviving MD patient (37 years) receiving early‐onset and long‐term copper treatment. He has few neurological symptoms without connective tissue disturbances; and a missense ATP7A variant, p.(Pro852Leu), which results in impaired protein trafficking while the copper transport function is spared. These findings suggest that some cuproenzymes maintain their function when sufficient copper is provided to the cells; and underline the importance of early initiated copper treatment, efficiency of which is likely to be dependent on the mutant ATP7A function.</description><identifier>ISSN: 0009-9163</identifier><identifier>EISSN: 1399-0004</identifier><identifier>DOI: 10.1111/cge.13083</identifier><identifier>PMID: 28657131</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Age ; ATP7A ; Child, Preschool ; Copper ; Copper - therapeutic use ; copper metabolism ; copper treatment ; Copper-transporting ATPases - metabolism ; copperhistidine ; Histidine ; Humans ; Infant ; Infant, Newborn ; Male ; Menkes disease ; Menkes Kinky Hair Syndrome - drug therapy ; Menkes Kinky Hair Syndrome - enzymology ; Menkes syndrome ; Patients ; Protein Transport ; residual function ; Supplements</subject><ispartof>Clinical genetics, 2017-11, Vol.92 (5), p.548-553</ispartof><rights>2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3343-cac854d8981e5c6f85d75a3d6e7f3a6227535e14ffd111e7dc87e5b99838590a3</citedby><cites>FETCH-LOGICAL-c3343-cac854d8981e5c6f85d75a3d6e7f3a6227535e14ffd111e7dc87e5b99838590a3</cites><orcidid>0000-0002-4777-5802</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28657131$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tümer, Z.</creatorcontrib><creatorcontrib>Petris, M.</creatorcontrib><creatorcontrib>Zhu, S.</creatorcontrib><creatorcontrib>Mercer, J.</creatorcontrib><creatorcontrib>Bukrinski, J.</creatorcontrib><creatorcontrib>Bilz, S.</creatorcontrib><creatorcontrib>Baerlocher, K.</creatorcontrib><creatorcontrib>Horn, N.</creatorcontrib><creatorcontrib>Møller, L.B</creatorcontrib><title>A 37‐year‐old Menkes disease patient—Residual ATP7A activity and early copper administration as key factors in beneficial treatment</title><title>Clinical genetics</title><addtitle>Clin Genet</addtitle><description>Menkes disease (MD) is a lethal disorder characterized by severe neurological symptoms and connective tissue abnormalities; and results from malfunctioning of cuproenzymes, which cannot receive copper due to a defective intracellular copper transporting protein, ATP7A. Early parenteral copper‐histidine supplementation may modify disease progression substantially but beneficial effects of long‐term treatment have been recorded in only a few patients. Here we report on the eldest surviving MD patient (37 years) receiving early‐onset and long‐term copper treatment. He has few neurological symptoms without connective tissue disturbances; and a missense ATP7A variant, p.(Pro852Leu), which results in impaired protein trafficking while the copper transport function is spared. These findings suggest that some cuproenzymes maintain their function when sufficient copper is provided to the cells; and underline the importance of early initiated copper treatment, efficiency of which is likely to be dependent on the mutant ATP7A function.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>ATP7A</subject><subject>Child, Preschool</subject><subject>Copper</subject><subject>Copper - therapeutic use</subject><subject>copper metabolism</subject><subject>copper treatment</subject><subject>Copper-transporting ATPases - metabolism</subject><subject>copperhistidine</subject><subject>Histidine</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Menkes disease</subject><subject>Menkes Kinky Hair Syndrome - drug therapy</subject><subject>Menkes Kinky Hair Syndrome - enzymology</subject><subject>Menkes syndrome</subject><subject>Patients</subject><subject>Protein Transport</subject><subject>residual function</subject><subject>Supplements</subject><issn>0009-9163</issn><issn>1399-0004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kTFP3TAUhS1UVF5pB_5AZalLGQJxbhzb49MThUogEKJz5GffVIbECXZClY21G0N_Ib8E00c7IOHlyNJ3zr26h5A9lh-w9A7NTzxgkEvYIgsGSmV5npfvyCKJyhSrYId8iPE6fUFw9Z7sFLLiggFbkN9LCuLx_mFGHZL0raVn6G8wUusi6oh00KNDPz7e_7nE6OykW7q8uhBLqs3o7tw4U-0tTfZ2pqYfBgxU2855F8eQrL2nOtIbnGmTDH2I1Hm6Ro-NMy5ljQH12KUBH8l2o9uIn150l_z4dnS1OslOz4-_r5anmQEoITPaSF5aqSRDbqpGciu4BluhaEBXRSE4cGRl09h0GhTWSIF8rZQEyVWuYZd83eQOob-dMI5156LBttUe-ynWTLGSyyIvqoR-eYVe91PwabtElRJKoeCZ2t9QJvQxBmzqIbhOh7lmef3cT536qf_2k9jPL4nTukP7n_xXSAION8Av1-L8dlK9Oj7aRD4BiTicng</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Tümer, Z.</creator><creator>Petris, M.</creator><creator>Zhu, S.</creator><creator>Mercer, J.</creator><creator>Bukrinski, J.</creator><creator>Bilz, S.</creator><creator>Baerlocher, K.</creator><creator>Horn, N.</creator><creator>Møller, L.B</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4777-5802</orcidid></search><sort><creationdate>201711</creationdate><title>A 37‐year‐old Menkes disease patient—Residual ATP7A activity and early copper administration as key factors in beneficial treatment</title><author>Tümer, Z. ; Petris, M. ; Zhu, S. ; Mercer, J. ; Bukrinski, J. ; Bilz, S. ; Baerlocher, K. ; Horn, N. ; Møller, L.B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3343-cac854d8981e5c6f85d75a3d6e7f3a6227535e14ffd111e7dc87e5b99838590a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>ATP7A</topic><topic>Child, Preschool</topic><topic>Copper</topic><topic>Copper - therapeutic use</topic><topic>copper metabolism</topic><topic>copper treatment</topic><topic>Copper-transporting ATPases - metabolism</topic><topic>copperhistidine</topic><topic>Histidine</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Menkes disease</topic><topic>Menkes Kinky Hair Syndrome - drug therapy</topic><topic>Menkes Kinky Hair Syndrome - enzymology</topic><topic>Menkes syndrome</topic><topic>Patients</topic><topic>Protein Transport</topic><topic>residual function</topic><topic>Supplements</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tümer, Z.</creatorcontrib><creatorcontrib>Petris, M.</creatorcontrib><creatorcontrib>Zhu, S.</creatorcontrib><creatorcontrib>Mercer, J.</creatorcontrib><creatorcontrib>Bukrinski, J.</creatorcontrib><creatorcontrib>Bilz, S.</creatorcontrib><creatorcontrib>Baerlocher, K.</creatorcontrib><creatorcontrib>Horn, N.</creatorcontrib><creatorcontrib>Møller, L.B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tümer, Z.</au><au>Petris, M.</au><au>Zhu, S.</au><au>Mercer, J.</au><au>Bukrinski, J.</au><au>Bilz, S.</au><au>Baerlocher, K.</au><au>Horn, N.</au><au>Møller, L.B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A 37‐year‐old Menkes disease patient—Residual ATP7A activity and early copper administration as key factors in beneficial treatment</atitle><jtitle>Clinical genetics</jtitle><addtitle>Clin Genet</addtitle><date>2017-11</date><risdate>2017</risdate><volume>92</volume><issue>5</issue><spage>548</spage><epage>553</epage><pages>548-553</pages><issn>0009-9163</issn><eissn>1399-0004</eissn><abstract>Menkes disease (MD) is a lethal disorder characterized by severe neurological symptoms and connective tissue abnormalities; and results from malfunctioning of cuproenzymes, which cannot receive copper due to a defective intracellular copper transporting protein, ATP7A. Early parenteral copper‐histidine supplementation may modify disease progression substantially but beneficial effects of long‐term treatment have been recorded in only a few patients. Here we report on the eldest surviving MD patient (37 years) receiving early‐onset and long‐term copper treatment. He has few neurological symptoms without connective tissue disturbances; and a missense ATP7A variant, p.(Pro852Leu), which results in impaired protein trafficking while the copper transport function is spared. These findings suggest that some cuproenzymes maintain their function when sufficient copper is provided to the cells; and underline the importance of early initiated copper treatment, efficiency of which is likely to be dependent on the mutant ATP7A function.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>28657131</pmid><doi>10.1111/cge.13083</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4777-5802</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-9163 |
ispartof | Clinical genetics, 2017-11, Vol.92 (5), p.548-553 |
issn | 0009-9163 1399-0004 |
language | eng |
recordid | cdi_proquest_miscellaneous_1914582026 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Adolescent Adult Age ATP7A Child, Preschool Copper Copper - therapeutic use copper metabolism copper treatment Copper-transporting ATPases - metabolism copperhistidine Histidine Humans Infant Infant, Newborn Male Menkes disease Menkes Kinky Hair Syndrome - drug therapy Menkes Kinky Hair Syndrome - enzymology Menkes syndrome Patients Protein Transport residual function Supplements |
title | A 37‐year‐old Menkes disease patient—Residual ATP7A activity and early copper administration as key factors in beneficial treatment |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A39%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%2037%E2%80%90year%E2%80%90old%20Menkes%20disease%20patient%E2%80%94Residual%20ATP7A%20activity%20and%20early%20copper%20administration%20as%20key%20factors%20in%20beneficial%20treatment&rft.jtitle=Clinical%20genetics&rft.au=T%C3%BCmer,%20Z.&rft.date=2017-11&rft.volume=92&rft.issue=5&rft.spage=548&rft.epage=553&rft.pages=548-553&rft.issn=0009-9163&rft.eissn=1399-0004&rft_id=info:doi/10.1111/cge.13083&rft_dat=%3Cproquest_cross%3E1948347936%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3343-cac854d8981e5c6f85d75a3d6e7f3a6227535e14ffd111e7dc87e5b99838590a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1948347936&rft_id=info:pmid/28657131&rfr_iscdi=true |